Inmed Pharmaceuticals In (IN.CN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 06/30
| 06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 6,572 | 7,601 | 9,535 | 6,738 | 8,913 |
| Receivables | 353 | 208 | 373 | 166 | 260 |
| Inventories | 1,244 | 1,194 | 745 | 1,133 | 1,616 |
| Other current assets | 521 | 1,062 | 1,157 | 258 | 542 |
| TOTAL | $8,690 | $10,064 | $11,810 | $8,295 | $11,332 |
| Non-Current Assets | |||||
| PPE Net | 1,250 | 1,371 | 1,481 | 615 | 723 |
| Intangibles | 1,783 | 1,824 | 1,864 | 1,905 | 1,946 |
| Other Non-Current Assets | 100 | 100 | 100 | 102 | 105 |
| TOTAL | $3,133 | $3,295 | $3,445 | $2,622 | $2,775 |
| Total Assets | $11,823 | $13,359 | $15,255 | $10,917 | $14,106 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 626 | 403 | 306 | 380 | 544 |
| Accrued Expenses | 540 | 576 | 559 | 387 | 522 |
| TOTAL | $1,972 | $1,529 | $1,680 | $1,339 | $2,001 |
| Non-Current Liabilities | |||||
| TOTAL | $645 | $725 | $803 | $0 | $16 |
| Total Liabilities | $2,617 | $2,254 | $2,483 | $1,339 | $2,017 |
| Shareholders' Equity | |||||
| Common Shares | 82,784 | 80,607 | 79,937 | 77,620 | 77,620 |
| Retained earnings | -109,076 | -107,138 | -105,415 | -103,937 | -101,400 |
| Other shareholders' equity | 129 | 129 | 129 | 129 | 129 |
| TOTAL | $9,206 | $11,105 | $12,772 | $9,578 | $12,090 |
| Total Liabilities And Equity | $11,823 | $13,359 | $15,255 | $10,917 | $14,106 |